Acotinib/Acalabrutinib vs. Zaubrutinib: Which BTK inhibitor is better?

Acalabrutinib/Acalabrutinib and Zanubrutinib, two high-profile Bruton’s tyrosine kinase (BTK) inhibitors, have shown significant efficacy in the treatment of B-cell malignancies. Their therapeutic effects on diseases such as mantle cell lymphoma and chronic lymphocytic leukemia have attracted much attention. However, the two drugs have subtle differences in their mechanisms of action and side effects, making which drug to choose a matter of careful consideration for patients and physicians.

Acotinib, with acalabrutinib as its active ingredient, is known as the second-generation BTK inhibitor. Its efficacy in treating certain lymphomas, especially mantle cell lymphoma (MCL), has been clinically proven. The selective inhibition of BTK by acotinib means it may produce fewer off-target effects, thereby reducing the risk of side effects. This property makes acotinib an effective treatment option for patients with relapsed or refractory MCL.

On the other hand, zanubrutinib useszanubrutinib as its active ingredient, which is another drug with highly effective BTK inhibitory effect. It has shown significant therapeutic effects in a variety of lymphoma types, including MCL, Wadenström's macroglobulinemia (WM), and marginal zone lymphoma (MZL). The high affinity of zanubrutinib for BTK may give it a stronger BTK inhibitory effect, but it may also increase the risk of side effects.

When choosing acotinib or zanubrutinib, doctors and patients need to comprehensively consider the patient's specific indications, previous treatment, potential drug interactions, and risk of side effects. While both drugs are important advances in the treatment of B-cell lymphoma, the best choice still depends on the individual situation. Therefore, it is important to seek the advice of your doctor before making a decision.